BDSX

Biodesix Inc

Add to Watchlist

Advanced Chart

0.401

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.4005

Open

0.4005

VWAP

0.40

Vol

196.00K

Mkt Cap

58.73M

Low

0.4005

Amount

78.50K

EV/EBITDA(TTM)

Total Shares

114.69M

84.80M

EV/OCF(TTM)

P/S(TTM)

0.77

Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

20.85M

+14.87%

24.58M

+20.34%

23.55M

+31.14%

Estimates Revision

The market is revising Downward the revenue expectations for Biodesix, Inc. (BDSX) for FY2025, with the revenue forecasts being adjusted by -10.03% over the past three months. During the same period, the stock price has changed by 11.44%.

Revenue Estimates for FY2025

Revise Downward

-10.03%

In Past 3 Month

Stock Price

Go Up

+11.44%

In Past 3 Month

6 Analyst Rating

369.41% Upside

Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is 1.88 USD with a low forecast of 1.50 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

369.41% Upside

Current: 0.401

Low

1.50

Averages

1.88

High

2.00

369.41% Upside

Current: 0.401

Low

1.50

Averages

1.88

High

2.00

Scotiabank

Outperform

NULL

downgrade

$3 -> $2

2025-05-21

Reason

Scotiabank

Price Target

$3 -> $2

2025-05-21

downgrade

Outperform

NULL

Reason

Scotiabank lowered the firm's price target on Biodesix to $2 from $3 and keeps an Outperform rating on the shares. The company's Q1 revenue miss and FY25 revenue guidance reduction can be attributed to the shift in the company's commercial strategy, the analyst tells investors. The firm continues to believe the market for lung nodule risk assessment is a multi-billion-dollar opportunity that is under-penetrated and the company faces minimal competition.

William Blair

Outperform -> Market Perform

downgrade

2025-05-14

Reason

William Blair

Price Target

2025-05-14

downgrade

Outperform -> Market Perform

Reason

William Blair downgraded Biodesix to Market Perform from Outperform. The company lowered its full-year revenue guidance by 12% at the midpoint to reflect slower salesforce rep hiring and slightly higher rep attrition than expected, the analyst tells investors in a research note. The firm believes the Q1 update puts the stock in "show me status" until likely the latter part of 2025 or early 2026. The shares "may have a ceiling on them" even at what is a "very discounted valuation," contends William Blair.

Canaccord

Kyle Mikson

Buy

downgrade

2025-05-14

Reason

Canaccord

Kyle Mikson

Price Target

2025-05-14

downgrade

Buy

Reason

Canaccord analyst Kyle Mikson lowered the firm's price target on Biodesix to $1.50 from $2.50 and keeps a Buy rating on the shares. The firm said the target decrease is driven by lower near- and long-term revenue estimates after the company posted Q1 results that were below expectations.

TD Cowen

Buy

downgrade

$3 -> $2

2025-05-14

Reason

TD Cowen

Price Target

$3 -> $2

2025-05-14

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Biodesix to $2 from $3 and keeps a Buy rating on the shares. The firm updated its model as sales force issues were a drag on 1Q results and the guide down.

Craig-Hallum

Buy

downgrade

2025-05-14

Reason

Craig-Hallum

Price Target

2025-05-14

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on Biodesix to $1.50 from $3 and keeps a Buy rating on the shares. The firm believes Biodesix is likely to sell off even further on a Q1 volume and revenue miss and lowered guidance. The company cites disruption from a sales force reorganization. Craig-Hallum expects it will take a few quarters for the company to get back on the right track, and thus has revised its estimates below the low end of the new guidance range.

Lake Street

Buy

downgrade

$3 -> $2

2025-05-14

Reason

Lake Street

Price Target

$3 -> $2

2025-05-14

downgrade

Buy

Reason

Lake Street lowered the firm's price target on Biodesix to $2 from $3 and keeps a Buy rating on the shares after the company reported Q1 revenue short of the firm's estimate and consensus and reduced 2025 revenue guidance to $80M-$85M from $92M-$95M. Following the report, the firm reduced its price target to reflect multiple compression and near-term uncertainty surrounding the implementation of the new sales infrastructure.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Biodesix Inc (BDSX.O) is -2.03, compared to its 5-year average forward P/E of -5.22. For a more detailed relative valuation and DCF analysis to assess Biodesix Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.22

Current PE

-2.03

Overvalued PE

-0.05

Undervalued PE

-10.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.43

Current EV/EBITDA

-24.29

Overvalued EV/EBITDA

-1.02

Undervalued EV/EBITDA

-17.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

3.40

Current PS

0.63

Overvalued PS

6.13

Undervalued PS

0.66

Financials

Annual

Quarterly

FY2025Q2

YoY :

+11.68%

20.02M

Total Revenue

FY2025Q2

YoY :

+18.64%

-9.69M

Operating Profit

FY2025Q2

YoY :

+6.11%

-11.47M

Net Income after Tax

FY2025Q2

YoY :

-0.00%

-0.08

EPS - Diluted

FY2025Q2

YoY :

-67.61%

-6.66M

Free Cash Flow

FY2025Q2

YoY :

+1.90%

79.86

Gross Profit Margin - %

FY2025Q2

YoY :

-4.99%

-57.29

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

2.1K

USD

6-9

Months

135.2K

USD

0-12

Months

7.4K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

821.5K

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1991.2% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

2.1K

USD

6-9

Months

135.2K

USD

0-12

Months

7.4K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

821.5K

USD

Months

BDSX News & Events

Events Timeline

2025-06-10 (ET)

2025-06-10

06:19:59

Biodesix partners with Association of Pulmonary APPs for lung cancer education

2025-05-13 (ET)

2025-05-13

16:13:20

Biodesix cuts FY25 revenue view to $80M-$85M from $92M-$95M

2025-05-13

16:11:56

Biodesix reports Q1 EPS (8c) vs. (14c) last year

News

7.5

06-10Newsfilter

Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

7.5

06-10Yahoo Finance

Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

2.0

05-22TipRanks

3 Penny Stocks to Watch Now, 5/22/25